Alcohol and drug use is a common behavior among adolescents in the United States and other developed countries. A significant number of adolescents manifest problems with their substance use and may meet diagnostic criteria for a substance use disorder (SUD). The treatment of adolescent SUDs has begun to reflect the multifaceted nature of antecedents that lead to SUDs. These multiple problems need to be targeted for effective treatment. An empirical literature of treatment research for adolescents is emerging and provides clinicians with models and guidance for intervention with this often-difficult population.
disorders. SUDs are defined for alcohol, amphetamine (or amphetamine-like), caffeine, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine (or phencyclidine-like), and sedative, hypnotic, or anxiolytic agents.

Although the *DSM-IV-TR* diagnoses of substance abuse and substance dependence assist clinicians in identifying adolescents with pathological patterns of substance use, the *DSM-IV-TR* criteria, developed for adults, have not been established as applicable to adolescents (Martin and Winters, 1998). While *DSM-IV-TR* remains the guide for determining substance use–related pathology in adolescents, it is important to recognize the frequent differences between the most common manifestations of the diagnoses of substance abuse and dependence in adolescents versus adults. While substance use is a necessary prelude to abuse or dependence and early onset of regular use further increases the risk of SUDs, substance use per se is not sufficient for a diagnosis of abuse or dependence.

The diagnosis of *substance abuse* requires evidence of a maladaptive pattern of substance use with clinically significant levels of impairment or distress. Impairment means an inability to meet major role obligations leading to reduced functioning in one or more major areas of life, risk-taking behavior, an increase in the likelihood of legal problems due to possession, and exposure to hazardous situations. *Substance dependence* requires a substantial degree of involvement with a substance as evidenced by the adolescent’s meeting at least three criteria from a group of seven criteria such as withdrawal, tolerance, and loss of control over use.

**CLINICAL PRESENTATION**

Despite similarities to adults in physical size and abilities, most adolescents have not obtained mature levels of cognitive, emotional, social, or physical growth. They are challenged by the developmental tasks of forming a separate identity and preparing for appropriate societal and individual roles including job, marriage, and family. Within a developmental context, adolescents experiment with a wide range of attitudes and behaviors including the use of psychoactive substances. Most adolescents experiment with using substances such as alcohol and cigarettes, and a portion of them later advance to the use of marijuana; a smaller portion proceed to the use of other drugs (Kandel, 2002). The early onset of substance use and a more rapid progression through the stages of substance use are among the risk factors for the development of SUDs (Robins and McEvoy, 1990).

Youths who present with substance use and frequent intoxication often manifest significant levels of acute change in mood, cognition, and behavior (Bukstein and Tarter, in press). Behavioral changes may include disinhibition, lethargy, hyperactivity or agitation, somnolence, and hypervigilance. Changes in cognition may include impaired concentration, changes in attention span, and perceptual and overt disturbances in thinking such as delusions. Mood changes can range from depression to euphoria. The manifestations of substance use and intoxication vary with the type of substance(s) used, the amount used during a given time period, the setting and context of use, and a host of characteristics of the individual such as experience with the substance, expectations of drug effect, and the presence or absence of other psychopathology.

A hallmark of SUDs in adolescents is impairment in psychosocial and academic functioning (Martin and Winters, 1998). Impairment can include family conflict or dysfunction, interpersonal conflict, and academic failure. Associated characteristics include deviant and risk-taking behavior and comorbid psychiatric disorders such as conduct disorder, attention-deficit/hyperactivity disorder (ADHD), and mood, anxiety, and learning disorders (Bukstein et al., 1989; King et al., 2000; Lewinsohn et al., 1993). Almost all psychoactive substances, including those available to adults such as alcohol and nicotine, are illegal for adolescents to obtain, possess, and use. Some of the negative consequences of substance use for adolescents follow from the illegal nature of these substances rather than from their actual use.

The course of SUDs in adolescents is variable (Jaffe and Simkin, 2002; Jaffe and Solhkhah, 2004). Adolescents with abuse often decrease or discontinue use in late adolescence or early adulthood, while those with dependence and more risk factors are more likely to continue to meet criteria for one or more SUDs.

**EPIDEMIOLOGY**

Although the use of many substances among adolescents has declined substantially in recent years, substances such as opiates, LSD, inhalants, and steroids have shown periodic increases among youths in the past
several decades (University of Michigan, 2003). In community studies, the lifetime diagnosis of alcohol abuse ranged from 0.4% in the Great Smoky Mountain Study (Costello et al., 1996) to 9.6% in the National Comorbidity Study (Kessler et al., 1994). The lifetime diagnosis of alcohol dependence ranged from 0.6% (Costello et al., 1996) to 4.3% in the Oregon Adolescent Depression Project (Lewinsohn et al., 1996). The lifetime prevalence of drug abuse or dependence has ranged from 3.3% in 15-year-olds to 9.8% in 17- to 19-year-olds (Kashani et al., 1987; Reinherz et al., 1993). It is notable that the age at which experimentation begins has been gradually declining, especially for inhalants.

RISK FACTORS

The literature on the development of substance use and SUDs in adolescents has identified an assortment of individual, peer, family, and community risk factors (Brook et al., 1989; Newcomb, 1997). These risk factors reflect both genetic and environmental influences (Kendler et al., 1999; Weinberg et al., 1998). Put in a developmental context, genetic predispositions to affective, cognitive, and behavioral dysregulation and other temperamental deviations are exacerbated by family and peer factors and the developmental issues of puberty leading to substance use and pathological use (Dawes et al., 2000; Tarter et al., 1999). Psychopathology, especially in the form of early onset of disruptive behavior disorders and mood and anxiety disorders, may be associated with the etiology of SUDs (Armstrong and Costello, 2002; Loeber, 1988).

Developmental factors that contribute to early use or to continuing use include common adolescent feelings of being invulnerable, issues of autonomy, and peer influences or “peer pressure.” Emerging evidence suggests that childhood sexual abuse and other traumatic life events may be risk factors for later SUDs (Kendler et al., 2000). Children and preadolescents are particularly susceptible to cultural factors such as media promotion of substance use, which may influence the initial use of such gateway substances as tobacco (Resnik, 1990; Saffer, 2002).

PREVENTION

Most prevention efforts are based on various theoretical models of adolescent substance use/abuse development. Research has established a number of empirically based prevention interventions that primarily involve strengthening resilience factors and reducing risk factors for the development of SUDs (National Institute on Drug Abuse, 2003). Early intervention for psychopathology in youths at risk of SUDs is critical to prevent early-onset substance use and SUDs.

RECOMMENDATIONS

Each recommendation in this parameter is identified as falling into one of the following categories of endorsement, indicated by an abbreviation in brackets following the statement. These categories indicate the degree of importance or certainty of each recommendation.

[MS] Minimal standards are recommendations that are based on substantial empirical evidence (such as well-controlled, double-blind trials) or overwhelming clinical consensus. Minimal standards are expected to apply more than 95% of the time, i.e., in almost all cases. When the practitioner does not follow this standard in a particular case, the medical record should indicate the reason.

[CG] Clinical guidelines are recommendations that are based on empirical evidence (such as open trials, case studies) and/or strong clinical consensus. Clinical guidelines apply approximately 75% of the time. These practices should always be considered by the clinician, but there are exceptions to their application.

[OP] Options are practices that are acceptable but not required. There may be insufficient empirical evidence to support recommending these practices as minimal standards or clinical guidelines. In some cases, they may be the perfect thing to do, but in other cases, they should be avoided. If possible, the practice parameter will explain the pros and cons of these options.

[NE] Not endorsed refers to practices that are known to be ineffective or contraindicated.

The recommendations of this parameter are based on a thorough review of the literature as well as clinical consensus. The following coding system is used to indicate the nature of the research that supports the recommendations.

[rdb] Randomized, double-blind clinical trial is a study of an intervention in which subjects are randomly assigned to either treatment or control groups and both subjects and investigators are blind to the assignments.
Randomized clinical trial is a study of an intervention in which subjects are randomly assigned to either treatment or control groups.

Clinical trial is a prospective study in which an intervention is made and the results are followed longitudinally.

CONFIDENTIALITY

Recommendation 1. The clinician should observe an appropriate level of confidentiality for the adolescent during the assessment and treatment [MS]

Adolescents are more likely to provide truthful information if they believe that their information, at least detailed information, will not be shared. Before the adolescent interview, the clinician should review exactly what information the clinician is obliged to share and with whom. Although it is obvious to the clinician that a court-ordered evaluation means a full report to the judge or probation officer, the adolescent may not be aware of this. The clinician should explicitly inform the adolescent of this requirement. Typically, a clinician should inform the adolescent that a threat of danger to self or others will force the clinician to inform a responsible adult, usually the parents. The clinician should be knowledgeable about local and federal laws that limit what information may be released. Most states have confidentiality laws that restrict the information that the clinician is allowed to share with anyone unless the adolescent provides consent. This includes information about deviant behavior such as selling drugs, who sells the adolescent drugs, and peer behaviors. The clinician should encourage and support the adolescent’s revealing the extent of substance use and other problems to parents. In other cases, the clinician should discuss what information that the adolescent will allow the clinician to reveal such as a general recommendation for treatment or impressions rather than a detailed report of specific deviant and substance use behaviors.

SCREENING

Recommendation 2. The mental health assessment of older children and adolescents requires screening questions about the use of alcohol and other substances of abuse [MS]

In the face of problems in one or more domains of adolescent functioning, clinicians and educational professionals who work with youths often need to screen for the need for more comprehensive evaluation. At the very least, screening involves asking about substance use. Asking about quantity and frequency, the presence of adverse consequences of use, and the adolescent’s attitude toward use are basic lines of screening inquiry. Several examples of screening instruments with established psychometric properties are listed in Table 1.

EVALUATION

Recommendation 3. If the screening raises concerns about substance use, the clinician should conduct a more formal evaluation to determine the quantity and frequency of use and consequences of use for each substance used and whether the youth meets criteria for SUD(s) [MS]

The goal of the evaluation is to determine whether the adolescent is using one or more substances, what effects substance use has on various domains of the adolescent’s psychosocial functioning, and whether the problem fits diagnostic criteria for substance abuse or dependence. To be considered a disorder, substance use must produce some level of dysfunction in one or more domains of the adolescent’s life. These include psychiatric/behavioral, family, school/vocational, recreational/leisure, and

### TABLE 1

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Ref.</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRAFFT</td>
<td>Knight et al., 2002</td>
<td>6 items; brief screen for primary care professionals</td>
</tr>
<tr>
<td>The Drug Use Screening Inventory–Adolescents (DUSI-A)</td>
<td>Tarter, 1990</td>
<td>159 items; documents the level of involvement with a variety of drugs and quantifies severity of consequences associated with drug use</td>
</tr>
<tr>
<td>Problem-Oriented Screening Instrument for Teenagers (POSIT)</td>
<td>Gruenewald and Kliitner, 1991</td>
<td>139 items; designed to identify problems and potential need for service in 10 functional areas, including substance use and abuse</td>
</tr>
<tr>
<td>Personal Experience Screening Questionnaire (PESQ)</td>
<td>Winters, 1992</td>
<td>40 items; screens for the need for further assessment of drug use disorders</td>
</tr>
</tbody>
</table>
medical domains (Rahdert, 1991; Tarter, 1990). Because of the covert nature of substance use, optimal assessment often requires information from a variety of sources including the adolescent, parents (or other caregivers), other family members, school, any involved social agencies, and previous treatment records.

The attitude of the clinician should be nonjudgmental and flexible regarding the order of the interview elements to ensure a valid report of substance use and associated problems.

The parent should be able to provide information about a family history of SUDs and other psychiatric disorders, family functioning, stressors and supports, and community resources and risks.

Detailed assessment of the adolescent’s substance use behavior is an essential element of the interview. Inquiry into patterns of use should include information about the age at onset and progression of use for specific substances; circumstances, frequency, and variability of use; and the types of agents used. The clinician should ask about both direct and indirect consequences of use in the domains of family, school/vocational, social, and psychological functioning and medical problems. The interviewer should also inquire about the context of use, which pertains to the adolescent’s view of substance use; the adolescent’s expectations of use; the usual times and places of substance use; peer attitudes and use patterns; common behavioral or emotional antecedents and consequences of use; and the adolescent’s overall social milieu. Such an inquiry can take the form of a functional analysis, considering both antecedents and consequences of the substance use behaviors. Finally, the clinician should ask about the adolescent’s view of his or her substance use as a potential problem, document past or current attempts to control or stop substance use, and review the criteria for substance abuse and dependence (substance specific). Evaluating the adolescent’s readiness for treatment or stage of change may help determine the initial treatment goals or level of care.

The differential diagnosis of adolescent SUDs requires consideration that the reported domains of dysfunction attributed to substance use may actually be due to premorbid or concurrent problems such as disruptive behavior disorders, family issues, or academic problems. The frequent comorbidity of SUDs and other psychiatric disorders necessitates a comprehensive review of past and present psychopathology including a review of psychiatric symptoms and treatment history. Riggs and Davies (2002) suggest a timeline approach to sort out the relationship between comorbid psychopathology, substance use, and developmental events and to assist in formulating a differential diagnosis and comprehensive treatment plan.

The interview with the adolescent also includes elements common to all assessments of emotional and behavioral problems of adolescents (American Academy of Child and Adolescent Psychiatry, 1997). A comprehensive developmental, social, and medical history is a part of any complete assessment involving adolescents (Winters, 2001). Particularly important is a review of human immunodeficiency virus risk factors including sexual and other high-risk behaviors. Clinicians may use a variety of structured interviews and rating scales with established psychometric properties to supplement interview information (see Table 2 for examples).

Recommendation 4. Toxicology, through the collection of bodily fluids or specimens, should be a routine part of the formal evaluation and ongoing assessment of substance use both during and after treatment [MS]

Toxicological tests of bodily fluids, usually urine but also blood, and hair samples to detect the presence of specific substances should be part of the formal evaluation and ongoing assessment of substance use (Table 3). The optimal use of urine screening requires proper collection techniques including visualization of obtaining the sample, evaluation of positive results, and a specific plan of action should the specimen be positive for the presence of substance(s) (Casavant, 2002; Cole, 1997). The clinician should establish rules regarding the confidentiality of the results before testing. Because of the limited time that a drug will remain in the urine and possible adulteration, a negative result of urine testing does not indicate that the youth does not use drugs.

TREATMENT

Recommendation 5. Adolescents with SUDs should receive specific treatment for their substance use [MS]

Reviews of the literature on adolescent treatment outcome have concluded that treatment is better than no treatment (Deas and Thomas, 2001; Williams and Chang, 2000). In the year after treatment, patients reported decreased heavy drinking, marijuana and other illicit drug use, and criminal involvement as well as
improved psychological adjustment and school performance (Grella et al., 2001; Hser et al., 2001). Longer duration of treatment is associated with several favorable outcomes. Pretreatment factors associated with poorer outcomes (usually substance use and relapse to use) are nonwhite race, increased seriousness of substance use, criminality, and lower educational status. The in-treatment factors predictive of outcome are time in treatment, involvement of family, use of practical problem solving, and provision of comprehensive services such as housing, academic assistance, and recreation. Posttreatment variables that are thought to be the most important determinants of outcome include association with non-using peers and involvement in leisure time activities, work, and school. Variables reported to be most consistently related to successful outcome are treatment completion, low pretreatment use, and peer and parent social support and nonuse of substances.

In terms of empirical support for specific treatment modalities, family therapy approaches have the most supporting evidence (Stanton and Shadish, 1997; Williams and Chang, 2000), although individual approaches such as cognitive-behavioral therapy (CBT), both alone and with motivational enhancement, have shown to be efficacious (Azrin et al., 2001 [rct]; Dennis et al., 2004 [rct]; Kaminer et al., 1998b, 1999 [rct]; Waldron et al., 2001 [rct]). Community reinforcement approaches using contingency contracting and vouchers also appear to be promising (Azrin et al., 1994 [ct]; Corby et al., 2000 [ct]; Godley et al., 2002 [rct]; Kaminer, 2000). Self-support groups can be encouraged as adjuncts to these treatment modalities.

The primary goal of the treatment of adolescents with SUDs is achieving and maintaining abstinence from substance use. While abstinence should remain the explicit, long-term goal of treatment, a realistic view recognizes

### TABLE 2

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Ref.</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adolescent Drug Abuse Diagnosis (ADAD)</td>
<td>Friedman and Utada, 1989</td>
<td>Provides severity rating on multiple domains of functioning</td>
</tr>
<tr>
<td>Adolescent Problem Severity Index (APSI)</td>
<td>Metzger et al., 1991</td>
<td>Provides severity ratings on multiple domains of functioning</td>
</tr>
<tr>
<td>Teen Addiction Severity Index (T-ASI)</td>
<td>Kaminer et al., 1993</td>
<td>Provides severity ratings on multiple domains of functioning</td>
</tr>
<tr>
<td>Comprehensive Adolescent Severity Index for Adolescents (CASI-A)</td>
<td>Meyers et al., 1995</td>
<td>Provides severity ratings on multiple domains of functioning</td>
</tr>
<tr>
<td>Global Appraisal of Individual Needs (GAIN)</td>
<td>Dennis, 1998</td>
<td>Documents substance use disorder and other psychiatric diagnoses; placement criteria; health, mental distress, and environment; and service use outcomes. A brief version allows for screening, and an outcome version provides information about critical outcome variables</td>
</tr>
<tr>
<td>Customary Drinking and Drug Use Record (CDDR)</td>
<td>Brown et al., 1998</td>
<td>Current and lifetime measures of 4 alcohol- and other drug-related domains</td>
</tr>
<tr>
<td>Adolescent Diagnostic Interview (ADI)</td>
<td>Winters and Henley, 1993</td>
<td>Assesses symptoms associated with substance use disorders. Obtains diagnoses, substance use history, and psychosocial functioning</td>
</tr>
</tbody>
</table>

### TABLE 3

<table>
<thead>
<tr>
<th>Substance</th>
<th>Detection After Last Use (days)</th>
<th>Half-life (hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamines</td>
<td>10–15 1–2</td>
<td>10–15</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>20–96 3–14</td>
<td>20–90 2–9</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>20–90 2–9</td>
<td>20–90 2–9</td>
</tr>
<tr>
<td>Cocaine</td>
<td>0.8–6.0 0.2–4</td>
<td>0.8–6.0 0.2–4</td>
</tr>
<tr>
<td>Methaqualone</td>
<td>20–60 7–14</td>
<td>20–60 7–14</td>
</tr>
<tr>
<td>Opiates</td>
<td>2–4 1–2</td>
<td>2–4 1–2</td>
</tr>
<tr>
<td>Phencyclidine (PCP)</td>
<td>7–16 2–8</td>
<td>7–16 2–8</td>
</tr>
<tr>
<td>Cannabinoids (THC)</td>
<td>10–40 2–8 (acute) 14–42 (chronic)</td>
<td>10–40 2–8 (acute) 14–42 (chronic)</td>
</tr>
</tbody>
</table>

Drugs not usually tested: LSD, psilocybin, MDMA, MDA, other designer drugs

THC = tetrahydrocannabinol; MDMA = methylene dioxymethamphetamine; MDA = 3,4-methylene dioxymethamphetamine.
both the chronicity of SUDs in some populations of adolescents and the self-limited nature of substance use and substance use–related problems in others. Given these considerations, harm reduction may be an interim, implicit goal of treatment. Included in the concept of harm reduction is a reduction in the use and adverse effects of substances, a reduction in the severity and frequency of relapses, and improvement in one or more domains of the adolescent’s functioning (e.g., academic performance or family functioning). While adolescents may not be initially motivated to stop substance use, the attainment of skills to deal with substance use may provide the adolescent with greater self-efficacy to not only reduce use but also ultimately move toward the goal of abstinence. Although harm reduction may be an interim goal of treatment, “controlled use” of any nonprescribed substance of abuse should never be an explicit goal in the treatment of adolescents. Control of substance use should not be the only goal of treatment. A broad concept of rehabilitation involves targeting associated problems and domains of functioning for treatment. Integrated interventions that concurrently deal with coexisting psychiatric and behavioral problems, family functioning, peer and interpersonal relationships, and academic/vocational functioning not only will produce general improvements in psychosocial functioning but most likely will yield improved outcomes in the primary treatment goal of achieving and maintaining abstinence.

Ongoing assessment of outcomes is important. The critical variables regarding current substance use are the use of specific substances during and after treatment with reference to the number of days of use per month, average amount per occasion, and maximum amount per occasion. Assessment of outcomes may also include determining the youth’s compliance with treatment and involvement in 12-step programs.

Based on the combination of empirical research and current clinical consensus, the clinician dealing with adolescents with SUDs should develop a treatment plan that uses modalities that target (1) motivation and engagement; (2) family involvement to improve supervision, monitoring, and communication between parents and adolescent; (3) improved problem solving, social skills, and relapse prevention; (4) comorbid psychiatric disorders through psychosocial and/or medication treatments; (5) social ecology in terms of increasing prosocial behaviors, peer relationships, and academic functioning; and (6) adequate duration of treatment and follow-up care.

Recommendation 6. Adolescents with SUDs should be treated in the least restrictive setting that is safe and effective [MS]

Treatment of adolescents with SUDs can take place at one of several levels of care, reflecting intensity of treatment and restriction of movement (American Academy of Child and Adolescent Psychiatry, 2001). Factors affecting the choice of treatment setting include the following: (1) the need to provide a safe environment and the ability of the adolescent to care for him- or herself; (2) motivation and willingness of the adolescent and his or her family to cooperate with treatment; (3) the adolescent’s need for structure and limit-setting that cannot be provided in a less restrictive environment; (4) the existence of additional medical or psychiatric conditions; (5) the availability of specific types of treatment settings for adolescents; (6) the adolescent’s and his or her family’s preferences for a particular setting; and (7) treatment failure in a less restrictive setting or level of care. Although residential programs, including therapeutic communities (Jainchill et al., 2000), have a place in the range of setting options, community intervention settings, if feasible, may offer optimal generalization of treatment gains. Even in the community, alternative sites such as home and school are being increasingly used (Brown, 2001; Wagner and Waldron, 2001).

Recommendation 7. Family therapy or significant family/parental involvement in treatment should be a component of treatment of SUDs [MS]

Family interventions are critical to the success of any treatment approach for adolescents with SUDs (Stanton and Shadish, 1997; Waldron, 1997) because a number of family-related factors, such as parental substance use or abuse, poor parent–child relationships, low perceived parental support, poor communication, and poor parental supervision and management of the adolescent’s behavior, have been identified as risk factors for the development of substance abuse among adolescents. Three domains of predictors that have figured prominently in longitudinal studies of the etiology of adolescent substance use and SUDs are particularly relevant: characteristics of the parent–child relationship; parental effectiveness; and parental SUDs. Conflict between parents and adolescents, insufficient parental monitoring, inconsistent or otherwise ineffective discipline, child abuse/neglect, and parental alcoholism or other substance
abuse have all been found to be robust correlates and predictors of adolescent substance use and SUDs (Hawkins et al., 1992).

Although there are many approaches to family intervention for substance abuse treatment, they have common goals: providing psychoeducation about SUDs, which decreases familial resistance to treatment and increases motivation and engagement; assisting parents and family to initiate and maintain efforts to get the adolescent into appropriate treatment and achieve abstinence; assisting parents and family to establish or reestablish structure with consistent limit-setting and careful monitoring of the adolescent’s activities and behavior; improving communication among family members; and getting other family members into treatment and/or support programs.

Family therapy is the most studied modality in the treatment of adolescents with SUDs. Based on the limited number of comparative studies, outpatient family therapy appears to be superior to other forms of outpatient treatment (Deas and Thomas, 2001; Waldron, 1997; Williams and Chang, 2000). Among the forms of family therapy having support based on controlled studies are functional family therapy (Alexander et al., 1990 [rct]; Friedman, 1989 [rct]), brief strategic family therapy (Szapocznik et al., 1983 [rct], 1988 [rct]), multisystemic therapy (Henggeler et al., 1991 [rct], 2002 [rct]), family systems therapy (Joanning et al., 1992 [rct]), and multidimensional family therapy (Dennis et al., 2002 [rct]; Liddle et al., 2001 [rct]). An integrated behavioral and family therapy model that combines a family systems model and CBT also appears efficacious (Waldron et al., 2001 [rct]).

Despite the importance of family interventions, treatment can be effective without participation of the adolescent (Dennis et al., 2004; Waldron et al., 2001). Similarly, interventions with the adolescent alone (e.g., CBT or CBT plus Motivational Enhancement Therapy [MET]) are also effective (Dennis et al., 2004; Kaminer and Burleson, 1999; Kaminer et al., 1998).

**Recommendation 8.** Treatment programs and interventions should develop procedures to minimize treatment dropout and to maximize motivation, compliance, and treatment completion [CG]

Treatment completion is the treatment variable most consistently related to positive outcome (Alford et al., 1991; Hser et al., 2001; Williams and Chang, 2000). Related variables are motivation and compliance, which are also related to better outcomes (Cady et al., 1996). Adolescent perceptions can also contribute to whether the youth will be engaged in treatment; this suggests that specialized, adolescent-focused engagement interventions are necessary.

Modifications of motivational interviewing or enhancement techniques for adolescents have shown promise for both evaluation and treatment based on limited treatment studies (Colby et al., 1998 [rct]; Monti et al., 1999 [rct], 2001). This nonjudgmental, nondirective strategy is designed to move the adolescent to a “stage of change” in which the youth is more receptive to treatment or behavior change. Motivational interviewing and other brief interventions may serve to heighten motivation, increase self-efficacy, and provide personalized feedback and education tailored to specific substances and comorbid problems such as psychiatric disorders.

Specific engagement procedures have been incorporated as part of many family-based interventions (Dakof et al., 2001 [rct]; Diamond et al., 1999; Santisteban et al., 1996 [rct]; Szapocznik et al., 1988 [rct]; Waldron, 1997 [rct]; Waldron et al., 2001 [rct]). Other family-based treatments such as multidimensional family therapy (Rowe et al., 2002) and multisystemic therapy (Henggeler et al., 1996; Randall et al., 2001) also have strong engagement goals and components.

**Recommendation 9.** Medication can be used when indicated for the management of craving and withdrawal and for aversion therapy [OP]

Medications used to target alcohol-related cravings (e.g., naltrexone, acamprosate, ondansetron) are increasingly used among adults and have been effective in case reports in adolescents (Solhkhah and Wilens, 1998). Their efficacy in adolescents has yet to be tested in controlled trials. These and aversive agents such as disulfiram could be considered for use in treatment-resistant adolescents.

Similarly, the use of medications to treat alcohol, benzodiazepine, or opiate withdrawal using medications, such as benzodiazepines (alcohol) and clonidine and buprenorphine (opiates), is not based on empirical research in adolescents but rather on research and experience with adults. Clinicians should use caution in considering pharmacological treatment for adolescents with comorbid SUDs and psychiatric disorders. The presence of SUDs or substance use may increase the potential for intentional or unintentional overdose with some
psychotropic medications, especially in combination with some substances of abuse.

**Recommendation 10.** Treatment should encourage and develop peer support, especially regarding the nonuse of substances [CG]

Having a supportive environment, especially parents and peers who do not use substances, is important for optimal outcomes (Brown et al., 2001; Myers et al., 1995).

A controversial element of traditional treatment programs is the widespread use of group treatment. There is substantial evidence that group treatment can have significant negative effects on outcomes (Dishion et al., 2001). Emerging data suggest that this iatrogenic effect may be limited to more deviant, conduct-disordered youths who nevertheless make up a substantial portion of the adolescent SUD treatment population. Other studies show positive effects for group modalities (Dennis et al., 2002 [rct]; Kaminer and Burleson, 1999 [rct]; Waldron et al., 2001 [rct]). Clinicians should take caution when forming groups for treatment and should consider alternative family-based or other modalities for more deviant youths.

**Recommendation 11.** Twelve-step approaches may be used as a basis for treatment. Attendance at Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) groups is an adjunct to professional treatment of SUDs and should be encouraged [CG]

Twelve-step approaches, using AA and NA as a basis for treatment, are perhaps the most common approaches for treatment and treatment programs in the United States. Attendance in aftercare treatment or self-support groups (e.g., AA or NA) is related to positive outcomes in several studies of adolescent SUD treatment (Alford et al., 1991; Williams and Chang, 2000; Winters et al., 2000). Several other studies have found that attendance at self-support or aftercare groups is associated with higher rates of abstinence and other measures of improved outcome, when compared with those not participating in such groups after treatment (Brown et al., 1994).

Twelve-step programs can be defined as having adolescents work on specific steps toward recovery, attendance at self-support groups (AA or NA), and obtaining the assistance of a sponsor who is another person in recovery from substance use problems. Developmentally appropriate, specific 12-step programs and self-support groups offer several benefits including a recovering (i.e., nonsubstance-using) peer group, available sponsors, and other types of support (Jaffe, 1990, 2001). Although 12-step programs may be effective for many adolescents, they have not been subject to controlled clinical trials.

**Recommendation 12.** Programs/interventions should attempt to provide comprehensive services in other domains (e.g., vocational, recreational, medical, family, and legal) [CG]

Programs with more comprehensive services such as vocational counseling, recreational activities, and medical services (including birth control) have better outcomes than programs without those services (Hser et al., 1999; Williams and Chang, 2000). Per the success of multisystemic therapy, programs that deal with the social ecology or total life circumstances of the adolescent are likely to produce more lasting benefits than those that do not.

**COMORBIDITY**

**Recommendation 13.** Adolescents with SUDs should receive thorough evaluation for comorbid psychiatric disorders [MS]

Significant rates of adolescents with coexisting SUDs and psychiatric disorders (disruptive behavior disorders, mood disorders, and anxiety disorders) are reported in both clinical and general populations (Armstrong and Costello, 2002; Grella et al., 2001; Lewinsohn et al., 1993; Simkin, 2004). Some psychiatric disorders such as disruptive behavior disorders and depressive disorders may increase the risk of the development of SUDs. Although researchers and clinicians have proposed the concept of adolescents using illicit substances as a form of self-medication for dysphoria or other psychiatric symptoms, no definitive studies are available (Bukstein and Tarter, in press). Furthermore, the comorbidity of psychiatric disorders, particularly conduct disorder and, to a lesser extent, major depressive disorder, may have an effect on substance use and related problems at both baseline and follow-up and may impair an adolescent’s ability to effectively engage in treatment (Riggs and Whitmore, 1999). Evidence suggests that depression increases the rate and rapidity of relapse (Cornelius et al., 2003). When compared with youths...
with SUDs with no comorbidities, the 63% of youths with comorbid disorders were more likely to be alcohol or other drug dependent and have more problems with family, school, and criminal involvement; they were more likely to use marijuana and hallucinogens and engage in delinquent behavior in the 12 months after treatment (Grella et al., 2001).

Disruptive behavior disorders are the most common psychiatric disorders diagnosed in adolescents with SUDs. Conduct disorder, including the component of aggression, usually precedes and accompanies adolescent SUD (Huizinga and Elliot, 1981; Loeber, 1988). ADHD is also often present in youths with SUDs (Wilens et al., 1994). Several studies have also linked SUDs with learning disabilities and sensory processing problems in adolescents (Tapert et al., 2002).

Mood disorders, particularly depression, frequently have an onset both preceding and consequent to the onset of substance use and SUDs in adolescents (Armstrong and Costello, 2002). The prevalence of depressive disorders in these studies of clinical populations ranged from 24% to more than 50%. SUDs among adolescents are also a risk factor for suicidal behaviors, including ideation, attempts, and completed suicide (Crumley, 1990; Lewinsohn et al., 1996).

A number of studies of clinical populations show high rates of anxiety disorders, especially posttraumatic stress disorder and social phobia, among youths with SUDs, ranging from 7% to more than 40% (Clark et al., 1995; Grella et al., 2001). Bulimia nervosa is also frequently associated with adolescents having SUDs (von Ranson et al., 2002). SUDs are very common among individuals, especially the young and chronically impaired, who have a diagnosis of schizophrenia (Kutcher et al., 1992).

**Recommendation 14. Comorbid conditions should be appropriately treated [MS]**

It is essential to treat psychiatric disorders that are comorbid with SUDs (Physician Leadership on National Drug Policy, 2002). Although the effects of integrated mental health and SUD treatment await more empirical study, the optimal treatment of adolescents with SUDs and psychiatric comorbidity presumably involves an integration of treatment modalities rather than merely concurrent or consecutive treatment with specific modalities for either SUD or psychiatric disorder(s) (Riggs and Davies, 2002).

Many cognitive-behavioral modalities (CBT) effective with adolescents with conduct disorder also are relevant for youths with coexisting SUDs (Kazdin, 1995). CBT can include elements directed toward substance use such as relapse prevention but also generic issues such as social skills, anger control, and problem solving.

Recent emerging research and experience suggest that pharmacotherapy can be used safely and effectively in adolescents with SUDs (Bukstein and Kithas, 2002; Solikhah and Wilens, 1998). Open trials with pemoline and bupropion for ADHD and fluoxetine for depression have shown promise (Riggs et al., 1996 [ct], 1997 [ct], 1998 [ct]; Cornelius et al., 2001 [ct]). More recently, a double-blind, placebo-controlled trial of a stimulant medication demonstrated the efficacy of medication improving ADHD symptoms in adolescents with comorbid ADHD and SUD. This study also demonstrated that medication treatment of ADHD alone, without specific SUD or other psychosocial treatment, did not decrease substance use (Riggs et al., 2004 [rdb]). Lithium, in a randomized, controlled trial (Geller et al., 1998 [rdb]), and selective serotonin reuptake inhibitors, in open trials (Cornelius et al., 2001 [ct]; Riggs et al., 1997 [ct]), have produced significant improvements in adolescents with SUDs and comorbid mood disorders.

Some commonly used pharmacological agents, such as psychostimulants and benzodiazepines, have inherent abuse potential. The risk of abuse of a therapeutic agent by the adolescent, his or her peer group, or family members should prompt a thorough assessment of the risk of this outcome (e.g., history of abuse of the agent, family/parental history of substance abuse or antisocial behavior). Often, parental or adult supervision of medication administration can alleviate concerns about potential abuse. The clinician should also consider alternative agents to psychostimulants, such as atomoxetine and bupropion, with a lower potential for abuse. The newer long-acting stimulant preparations may offer less potential for abuse or diversion due to their form of administration and the ability to more easily monitor and supervise once-daily dosing. However, their abuse potential has yet to be fully ascertained. Although many anxiety symptoms or disorders in adolescents can be treated successfully with psychosocial methods such as behavior therapy, the use of selective serotonin reuptake inhibitors, tricyclic antidepressants, or buspirone is preferred over the use of benzodiazepines.
AFTERCARE

Recommendation 15. Programs and interventions should provide or arrange for posttreatment aftercare [CG]

SUDs are often chronic disorders requiring ongoing intervention. Participation in aftercare services after treatment in a program is related to improved outcomes (Williams and Chang, 2000). Adolescents attending more intensive aftercare programs involving case management and community reinforcement were more likely than those who did not receive these services to be abstinent from marijuana and reduce their alcohol use at 3 months post-discharge (Godley et al., 2001 [rct], 2002 [rct]). After the acute treatment for substance use, ongoing attention should be paid to comorbid psychopathology and other comprehensive needs of the adolescent and his or her family. Self-support groups such as AA and NA are often an element of aftercare.

SCIENTIFIC DATA AND CLINICAL CONSENSUS

Practice parameters are strategies for patient management, developed to assist clinicians in psychiatric decision making. American Academy of Child and Adolescent Psychiatry practice parameters, based on evaluation of the scientific literature and relevant clinical consensus, describe generally accepted approaches to assess and treat specific disorders or to perform specific medical procedures. These parameters are not intended to define the standard of care, nor should they be deemed inclusive of all proper methods of care or exclusive of other methods of care directed at obtaining the desired results. The clinician, after considering all the circumstances presented by the patient and his or her family, the diagnostic and treatment options available, and available resources, must make the ultimate judgment regarding the care of a particular patient.

Disclosure: Dr. Bukstein has received research funding from McNeil Consumer and Specialty Pharmaceuticals, Shire Pharmaceuticals, and Noven Pharmaceuticals; has served as a consultant for McNeil Consumer and Specialty Pharmaceuticals, Shire Pharmaceuticals, and Forrest Laboratories; and is on the speaker’s bureau for McNeil Consumer and Specialty Pharmaceuticals. Members of the consensus group were asked to identify any conflicts of interest that they may have with respect to their role in reviewing and finalizing the content of this practice parameter. One or more of the consensus group members were on the speaker’s bureau for one or more of the following pharmaceutical companies: Abbott, Eli Lilly, GlaxoSmithKline, Janssen, Ortho-McNeil, Pfizer, Shire, and Wyeth.

REFERENCES


J. AM. ACAD. CHILD ADOLESC. PSYCHIATRY. 44:6, JUNE 2005

619
Cornelius JR, Bulstein OG, Birnbaum B et al. (2001), Fluoxetine in adolescents with major depression and an alcohol use disorder: an open label trial. Addict Behav 26:735–739
Cornelius JR, Maisto SA, Martin CS et al. (2003), Major depression associated with earlier alcohol relapse in treated teens with AUD. Addict Behav 28:381–386
Crumley FE (1990), Substance abuse and adolescent suicidal behavior. JAMA 263:3051–3056
Dennis ML, Titus JC, Diamond G et al. (2002), The Cannabis Youth Treatment (CYT) experiment: rationale, study design, and analysis plans. Addiction 97:16–34
Kessler RC, McGonagle KA, Zhao S et al. (1994), Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Study. Arch Gen Psychiatry 51:8–19


Monti PM, Colby SM, O’Leary TA (2001), Adolescents, Alcohol, and Substance Abuse: Reaching Teens through Brief Interventions. New York: Guilford


Sanisteban DA, Szapocznik J, Perez-Vidal A, Kurtines WM, Murray EJ, LaPerriere A (1996), Efficacy of intervention for engaging youth and families into treatment and some variables that may contribute to differential effectiveness. J Fam Psychol 10:35–44


Wagner EF, Waldron HB (2001), Innovations in Adolescent Substance Abuse Interventions. Amsterdam: Pergamon/Eleveier Science


Winters KC (1992), Development of an adolescent substance abuse screening questionnaire. Addict Behav 17:479–490

